S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.34 (+0.30%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.34 (+0.30%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.34 (+0.30%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
S&P 500   3,625.73 (-0.27%)
DOW   29,870.08 (-0.59%)
QQQ   295.34 (+0.30%)
AAPL   115.94 (+0.67%)
MSFT   212.95 (-0.43%)
FB   274.57 (-0.85%)
GOOGL   1,763.46 (-0.02%)
AMZN   3,175.65 (+1.85%)
TSLA   563.53 (+1.47%)
NVDA   525.45 (+1.38%)
BABA   276.03 (-1.40%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   62.99 (-1.50%)
AMD   86.25 (+1.39%)
T   28.99 (-0.82%)
NIO   53.15 (-0.67%)
F   9.12 (-3.49%)
ACB   8.66 (-6.18%)
NFLX   481.84 (-0.22%)
GILD   59.56 (-1.15%)
BA   219.59 (+0.50%)
DIS   148.73 (-1.82%)
Log in
NASDAQ:CYTK

Cytokinetics Stock Forecast, Price & News

$16.48
-0.01 (-0.06 %)
(As of 11/25/2020 11:58 AM ET)
Add
Compare
Today's Range
$16.42
Now: $16.48▼
$16.76
50-Day Range
$15.26
MA: $16.94▼
$28.61
52-Week Range
$8.00
Now: $16.48▼
$30.14
Volume17,695 shs
Average Volume1.12 million shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Read More
Cytokinetics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 4.4Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.92 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYTK
Previous Symbol
CUSIPN/A
CIK1061983
Webwww.cytokinetics.com
Phone650-624-3000
Employees156

Debt

Debt-to-Equity Ratio0.90
Current Ratio15.18
Quick Ratio15.17

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$26.87 million
Price / Sales43.41
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.11 per share
Price / Book7.81

Profitability

EPS (Most Recent Fiscal Year)($2.11)
Net Income$-121,690,000.00
Net Margins-209.88%
Return on Equity-3,065.14%
Return on Assets-36.39%

Miscellaneous

Outstanding Shares70,779,000
Market Cap$1.17 billion
Next Earnings Date3/2/2021 (Estimated)
OptionableOptionable
$16.48
-0.01 (-0.06 %)
(As of 11/25/2020 11:58 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

How has Cytokinetics' stock been impacted by COVID-19 (Coronavirus)?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CYTK shares have increased by 36.8% and is now trading at $16.46.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Cytokinetics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cytokinetics.

What stocks does MarketBeat like better than Cytokinetics?

Wall Street analysts have given Cytokinetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cytokinetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Cytokinetics.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its earnings results on Wednesday, November, 4th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.54. The biopharmaceutical company earned $41.69 million during the quarter, compared to the consensus estimate of $3.80 million. Cytokinetics had a negative net margin of 209.88% and a negative return on equity of 3,065.14%.
View Cytokinetics' earnings history.

What price target have analysts set for CYTK?

9 brokerages have issued 1 year price objectives for Cytokinetics' stock. Their forecasts range from $16.00 to $48.00. On average, they anticipate Cytokinetics' share price to reach $30.67 in the next twelve months. This suggests a possible upside of 86.3% from the stock's current price.
View analysts' price targets for Cytokinetics.

Who are some of Cytokinetics' key competitors?

Some companies that are related to Cytokinetics include Schrödinger (SDGR), PTC Therapeutics (PTCT), Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), Insmed (INSM), GW Pharmaceuticals (GWPH), TG Therapeutics (TGTX), ChemoCentryx (CCXI), Arena Pharmaceuticals (ARNA), FibroGen (FGEN), Legend Biotech (LEGN), Hypera (HYPMY), Apellis Pharmaceuticals (APLS) and MorphoSys (MOR).
View all competitors.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:
  • Mr. Robert I. Blum, CEO, Pres & Director (Age 56, Pay $905.58k)
  • Mr. Ching W. Jaw, Sr. VP & CFO (Age 57, Pay $549.19k)
  • Mr. David W. Cragg, Chief HR & Admin. Officer (Age 64, Pay $480.61k)
  • Mr. Mark A. Schlossberg, Sr. VP of Legal, Gen. Counsel & Sec. (Age 59, Pay $564.47k)
  • Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 56, Pay $652.43k)
  • Dr. James A. Spudich, Co-Founder & Member of Scientific Advisory Board (Age 78)
  • Mr. Robert Wong, VP & Chief Accounting Officer (Age 53)
  • Ms. Diane Weiser, Sr. VP of Corp. Communications & Investor Relations
  • Ms. Bonnie A. Charpentier, Sr. VP of Regulatory Affairs & Compliance (Age 68)
  • Dr. Andrew A. Wolff, Sr. VP and Sr. Fellow, Clinical R&D (Age 65)

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.26%), State Street Corp (5.36%), Wasatch Advisors Inc. (4.32%), Foresite Capital Management IV LLC (2.36%), Point72 Asset Management L.P. (2.27%) and Logos Global Management LP (1.06%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

Which institutional investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Voloridge Investment Management LLC, Logos Global Management LP, Cubist Systematic Strategies LLC, Pinnacle Associates Ltd., Employees Retirement System of Texas, Trexquant Investment LP, and Wells Fargo & Company MN. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Ching Jaw, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics.

Which institutional investors are buying Cytokinetics stock?

CYTK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., State Street Corp, Vivo Capital LLC, Wasatch Advisors Inc., Candriam Luxembourg S.C.A., Assenagon Asset Management S.A., and State of New Jersey Common Pension Fund D. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $16.46.

How big of a company is Cytokinetics?

Cytokinetics has a market capitalization of $1.17 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 156 workers across the globe.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.